Genentech BD: Alzheimer's continues to be a priority

Genentech's Tom Zioncheck sat down with BioPharma Dive to talk about the big biotech's work in Alzheimer's disease. 

By Lisa LaMotta • July 17, 2017

Valeant unloads Obagi in latest sell-off

The beleaguered company continues to sell assets in an effort to reduce debt and move the company forward.

By Lisa LaMotta • July 17, 2017

BDSI inks Canadian marketing deal

BioDelivery Sciences and Purdue Pharma will be dancing cheek to cheek to launch BDSI's buccal buprenorphine in Canada.

By Suzanne Elvidge • July 17, 2017

Prescribed Reading: Rumors, blood and history in the making

Rumors swirl about a new CEO at Teva, hemophilia drugs are getting exciting and the first CAR-T therapy could be coming. 

By Lisa LaMotta • July 14, 2017

Sunovion sheds asthma brands to focus on COPD

The Massachusetts drugmaker recently acquired rights to three COPD treatments from Novartis and hopes to soon win approval for its own developed therapy. 

By Suzanne Elvidge • July 14, 2017

Digital health funding hits record high in first half of 2017, Rock Health finds

Seven companies snared $100 million or more in funding during the second quarter.

By Meg Bryant • July 12, 2017

No game changer: Sanofi picks up flu vaccine

The French pharma is adding to its lofty vaccines portfolio with a quick bolt-on acquisition. 

By Lisa LaMotta • July 11, 2017

Stada takeover: All over again?

After last month's unsuccessful takeover attempt, Bain Capital and Cinven have secured Stada's support for a revised bid.

By Suzanne Elvidge • July 11, 2017

Novartis hits pause on Fovista agreement

The Swiss drugmaker is no longer obligated to develop and commercialize Ophthotech's drug, at least until data from the OPH1004 study becomes available.

By Jacob Bell • July 10, 2017

J&J drops stem cell partner Capricor

Janssen Biotech's decision not to exercise an option for a cardiology candidate has batted Capricor stock.

By Suzanne Elvidge • July 10, 2017

Prescribed Reading: I/O is the only game in town

Immuno-oncology dominates dealmaking, clinical trial data and regulatory action. 

By Lisa LaMotta • July 7, 2017

Acer aims for public listing through reverse merger

Struggling biotech Opexa gets a lift for shareholders as Acer takes over its shell.

By Suzanne Elvidge • July 7, 2017

Konica Minolta buys US genetic test maker in $1B deal

The Japanese imaging firm aims to play a bigger role in precision medicine and adding Ambry Genetics will give it the genetic testing capabilities it needs. 

By Suzanne Elvidge • July 7, 2017

Celgene makes play to strengthen PD-1 position

The big biotech is buying its way further into the PD-1 race through a deal with China's BeiGene. 

By Lisa LaMotta • July 6, 2017

Oxford BioMedica, Novartis link up on CAR-T drug production

The deal could provide more than $100 million to the U.K.-based gene therapy developer as well as long-term profitability, according to analysts.

By Jacob Bell • July 6, 2017

Roche snaps up diabetes startup mySugr

MySugr recently recorded its one millionth registered user on its digital diabetes management platform. 

By Suzanne Elvidge • July 5, 2017

Prescribed Reading: Gottlieb pushes for efficiency at FDA

The Chief is trying to fulfill promises, while deal activity continues to stagnate in the sector as the industry waits on news from Washington. 

By Lisa LaMotta • June 30, 2017

Prescribed Reading: What we know from BIO

A closer look at the trends everyone was talking about at BIO, FDA continues its approval spree and Novartis has heart. 

By Lisa LaMotta • June 23, 2017

Cell Medica boosts manufacturing capacity in cell therapy deal

The U.K. cell therapy company hopes to push forward with development of CGT Catapult's WT1 targeting T-cell receptor technology. 

By Suzanne Elvidge • June 21, 2017

Pricing pressures lower drug sales forecasts, new report finds

It was the first lowering of long-term sales expectations in the 10-year history of EvaluatePharma's World Preview reports.

By Jacob Bell • June 21, 2017

Report: Biopharma dealmaking set to level off

A new survey from InVentiv Health suggests 2017 may see M&A levels closer to recent historical norms rather than the peak seen in 2015.

By Ned Pagliarulo • June 21, 2017

Private equity firm snaps up Parexel

Pamplona Capital's $5 billion deal for Parexel is the latest in a string of takeovers and mergers that have shaken up the contract research space.

By Suzanne Elvidge • June 21, 2017

#BIO2017 Day 1 roundup: Saunders' popularity and BI's strategy

The first day of the Biotechnology Innovation Center conference kicked off in San Diego, attracting thousands of industry participants to the sunny convention center. 

By Lisa LaMotta • June 19, 2017

Prescribed Reading: ADA, Mylan, and an executive order?

The SGLT-2 category heats up at ADA, Mylan faces pressure from all sides, and President Trump might put his stamp on drug pricing.

By Lisa LaMotta • June 16, 2017

Pfizer builds out anti-infective reach with Basilea deal

The pharma giant has picked up commercialization rights for Basilea's Cresemba in Europe, adding another product to its ex-U.S. portfolio.

By Suzanne Elvidge • June 16, 2017